DEF 14C: BioNexus Gene Lab Corp. Announces Board Changes via Stockholder Written Consent

BioNexus Gene Lab Corp. announces the removal of eight directors and the election of three new directors via written consent from stockholders holding approximately 50.1% of voting securities.

Summary

• BioNexus Gene Lab Corp. has notified stockholders of corporate actions taken via written consent in lieu of an annual meeting.
• Stockholders holding approximately 50.1% of the voting securities as of November 2, 2023, removed eight directors: Yeat Min Fong, Chi Yuen Leong, Yee Ming Wong, Teng Fook Fong, Chee Keong Yap, Chak Hua Yew, Boon Teong Teoh, and Chai Ping Lin.
• The same stockholders nominated and elected three new directors: Koon Wai Wong, Wei Foong Lim, and Muhammad Azrul bin Abdul Hamid, for a term until the next annual meeting.
• The company is providing this information statement to comply with Regulation 14C of the Securities Exchange Act of 1934.
• The actions were authorized by Section 17-16-704 of the Wyoming Business Corporation Act.
• The record date for determining voting power was November 2, 2023, with 17,792,663 shares of Common Stock issued and outstanding.
• The new directors began serving their term on December 11, 2023, and their terms shall expire at the annual meeting of stockholders to be held in 2024.
• Su-Leng Tan Lee and Chee Keong Yap were also appointed to the Board effective December 11, 2023.

Sentiment

Score: 5

Explanation: The document is neutral in tone, primarily conveying information about board changes. The sentiment is neither overly positive nor negative, reflecting a factual announcement.

Positives

• The company is streamlining its board structure.
• The company is complying with regulatory requirements by providing this information statement.

Negatives

• Significant board turnover may indicate internal issues or disagreements.
• The removal of directors by a majority consent, rather than a unanimous vote, could suggest potential conflicts among shareholders.

Risks

• The change in board composition could lead to a shift in company strategy or operations.
• Potential disruption during the transition period with new directors assuming their roles.
• The company may face challenges in maintaining continuity and stability with significant board changes.

Future Outlook

The newly elected directors will serve until the next annual meeting of shareholders in 2024.

Management Comments

• Su-Leng Tan Lee, Chief Executive Officer, stated that the Information Statement is being furnished to stockholders to notify them of the corporate actions taken by written consent.

Industry Context

Board changes are common in publicly traded companies, often driven by performance, strategic shifts, or shareholder activism. This announcement reflects a significant shift in the leadership structure of BioNexus Gene Lab Corp.

Comparison to Industry Standards

• Board composition and governance practices vary across the biotechnology industry.
• Companies like Myriad Genetics and Exact Sciences have similar board structures with independent directors and specialized committees.
• The level of shareholder involvement in board changes can range from routine elections to contested proxy battles, with BioNexus Gene Lab Corp.'s action falling in the middle with a majority consent.

Management Changes

Legal Proceedings

• None of the Company's officers or directors are currently subject to any material legal proceedings or any other material proceedings in which an officer or director is a party adverse to the Company or has a material interest adverse to the Company.

Related Party Transactions

• In connection with our acquisition of Chemrex, Liong Tai Tan, our former Chief Operating Officer, was a Chemrex shareholder and received 14,553,543 shares of common stock in connection with the transaction.
• The Board reviews and approves all related party transactions.

Stakeholder Impact

• Shareholders are informed of the changes in the Board of Directors.
• Employees may experience changes in leadership and company direction.
• Customers and suppliers may see changes in business relationships and strategies.

Next Steps

• The new directors will assume their responsibilities.
• The company will proceed with its business operations under the guidance of the new board.
• The company will hold its next annual meeting of shareholders in 2024.

Key Dates

Keywords

Board of Directors, Written Consent, Corporate Governance, Stockholders, BioNexus Gene Lab Corp.